Evolution Research Group | Endeavor Clinical Trials
Status and phase
Conditions
Treatments
About
This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
151 participants in 2 patient groups
Loading...
Central trial contact
Matthew Shive, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal